Oncology generics launched by MSN Labs and Natco Pharma

Generics/News | Posted 29/10/2021 post-comment0 Post your comment

In late September 2021, MSN Labs launched Cabolong, a branded generic of Cabozantinib for treatment of renal cell carcinoma in India. This was followed by the early October announcement that in the US, Natco Pharma launched 10 mg strength everolimus tablets, an oncology generic of Novartis’ Afinitor.

84 MD002440

Cabolong in India
Cabolong, is the first branded generic of Cabozantinib in India. It is available in 20 mg, 40 mg, 60 mg strengths. At monthly prices below Rupees 10,000, it offers a more affordable treatment option than imported regimens that can cost hundreds of thousands of Rupees monthly.

Cabolong is manufactured in MSN Labs’ Hyderabad facility that has been approved by stringent global regulatory authorities, including US Food and Drug Administration (FDA) and EU good manufacturing practice (GMP). The more affordable kidney cancer treatment drug hopes to contribute to reducing the impact of India’s rising cancer rates.

Everolimus in the US
Natco Pharma’s marketing partner Breckenridge Pharmaceutical Inc launched the 10 mg strength everolimus tablets, Breckenridge previously launched Everolimus tablets in 2.5 mg, 5 mg and 7.5 mg strengths during the first quarter of 2021 in the US market. This joins Teva pharmaceuticals’ 10 mg strength generic of the product in the US market [1].

Everolimus is a derivative of rapamycin (also known as sirolimus) and inhibits the mTOR protein to limit cancer growth. It is a small molecule drug that can be used to treat various cancer types including advanced kidney cancer, pancreatic neuroendocrine tumours and some forms of breast cancer [1].

Related articles
Natco cancer generic approval and advances for Lannett asthma and diabetes products

Two additions to the South Korean generics market

FDA approves generics from Amneal and Dr Reddy’s, and Natco submits ANDA


The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View this week’s headline article: Los datos apoyan la intercambiabilidad de los biosimilares de la UE

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.


Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de esta semana: Los datos apoyan la intercambiabilidad de los biosimilares de la UE

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 


1. GaBI Online - Generics and Biosimilars Initiative. FDA approves generics for cancer and gout [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Oct 29]. Available from: www.gabionline.net/generics/news/FDA-approves-generics-for-cancer-and-gout

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010